Researchmoz added Most up-to-date research on “Analysis Of Oncolytic Virus: Market Landscape, Pipeline, Stakeholders, Deals, Industry Trends & Opportunities To 2017” to its huge collection of research reports.
The field of oncolytic viruses was quite dormant in the first decade of the 2000s, characterized by slow clinical progress due to hypercautiousness and low, albeit steady, investments. The takeover of BioVex by Amgen in late 2011, worth up to US$ 1 bln, has woken up the field and became a game changer together with the 2015 approval of the first oncolytic virus Imlygic developed by BioVex in regulated markets. In addition, it was increasingly recognized that oncolytic viruses not only were able to directly lyse cancer cells, but they also „freed“ tumor specific neoantigens, indirectly acting as a cancer vaccine.
3.1 Herpes Simplex Virus (HSV) – based Oncolytic Viruses
3.2 Adenoviruses – based Oncolytic Viruses
3.3 Vaccinia Virus – Based Oncolytic Viruses
3.4 Vesicular Stomatitis Virus – based Oncolytic Viruses
3.5 Newcastle Disease Virus – based Oncolytic Viruses
3.6 Various Oncolytic Viruses
4.1 HSV-based Oncolytic Viruses
4.1.1 Imlygic; talimogene laherparepvec; T-Vec; OncoVEX(GM-CSF)
4.1.3 HF10; TB-1401
4.1.4 HSV1716; seprehvir
4.2 Adenovirus-based Oncolytic Viruses